Impacto da pandemia de COVID‐19 no curso da urticária crônica espontânea refratária em tratamento com omalizumabe
Authors:
- Müge OlgaçMOMüge Olgaç
- Osman Ozan YeğitOYOsman Ozan Yeğit
- Şengül BeyazŞBŞengül Beyaz
- Nida ÖztopNÖNida Öztop
- Can TüzerCTCan Tüzer
- Deniz EyiceDEDeniz Eyice
- Pelin KaradağPKPelin Karadağ
- Raif CoşkunRCRaif Coşkun
- Semra DemirSDSemra Demir
- Bahaauddin ÇolakoğluBÇBahaauddin Çolakoğlu
- Suna BüyüköztürkSBSuna Büyüköztürk
- Aslı GelincikAGAslı Gelincik
Open Access
- 1 March 2023
- journal article
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 98 (2) , 189-197
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Effective omalizumab interval prolongation in the treatment of chronic urticariaThe Journal of Allergy and Clinical Immunology: In Practice, 2020
- Adaptation of the Fear of COVID-19 Scale: Its Association with Psychological Distress and Life Satisfaction in TurkeyInternational Journal of Mental Health and Addiction, 2020
- The pandemic of social media panic travels faster than the COVID-19 outbreakJournal of Travel Medicine, 2020
- How to discontinue omalizumab in chronic spontaneous urticaria?Allergy, 2018
- The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticariaAllergy, 2018
- Stress differentially affects fear conditioning in men and womenPsychoneuroendocrinology, 2013
- Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapyJournal of Allergy and Clinical Immunology, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaNew England Journal of Medicine, 2013
- Investigating the impact of sex and cortisol on implicit fear conditioning with fMRIPsychoneuroendocrinology, 2010
- The Neurocircuitry of Fear, Stress, and Anxiety DisordersNeuropsychopharmacology, 2009